| Dr Reddy's Labs |
Dr. Reddy's Laboratories announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding access to advanced GLP‑1 receptor agonist–based therapy for the management of type 2 diabetes in India. Dr. Reddy's has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company's Day‑1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India. |
| EMA India |
| EMA India will hold a meeting of the Board of Directors of the Company on 27 March 2026. |
| Fiberweb (India) |
| Fiberweb (India) will hold a meeting of the Board of Directors of the Company on 27 March 2026. |
| HFCL |
| HFCL will hold a meeting of the Board of Directors of the Company on 25 March 2026. |
| Piramal Finance. |
| Piramal Finance will hold a meeting of the Board of Directors of the Company on 27 March 2026. |